Lianhua Qingwen for the Rehabilitation of Patient With Coronavirus Infection

Shandong University

Status and phase

Enrolling

Phase 4

Conditions

Traditional Chinese Medicine

Coronavirus

Treatments

Drug: Lianhua Qingwen capsules

Study type

Interventional

Funder types

Other

Identifiers

NCT05625035

Lianhua Qingwen 2022

Details and patient eligibility

About

The patients with coronavirus infection usually have fever, respiratory symptoms, headache, toothache, muscle soreness, physical decline, and so on, while others are asymptomatic patients. It is urgent to find drugs to improve the long-term rehabilitation of symptomatic patients with coronavirus infection and decrease the duration of viral shedding in both symptomatic and asymptomatic patients. This study aims to investigate the efficacy and safety of Lianhua Qingwen capsules in patients with coronavirus infection. The duration of viral shedding and symptoms before discharge, as well as the negative conversion ratio and disappearance ratio of main symptoms after 7-day treatment, will be evaluated. 6-month follow-up will be performed to evaluate the effect of Lianhua Qingwen on all infection events and the long-term rehabilitation of the symptoms induced by coronavirus infection.

Enrollment

4,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

confirmed SARS-CoV-2 Infection by virus testing;
≥18 years of age;
informed consent provided.

Exclusion criteria

overt bacterial infection in the respiratory tract resulting from common pathologies, including primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;
asthma treated daily, chronic airway disease, respiratory bacterial infections (e.g., purulent tonsillitis), acute tracheobronchitis, sinusitis, otitis media, and further respiratory tract pathologies potentially affecting the trial's data analysis;
common pulmonary diseases (e.g., severe pulmonary interstitial lesions and bronchiectasis) confirmed by chest CT;
severe pneumonia requiring ventilator use;
previous or present diseases potentially affecting trial participation or influencing study outcome, based on the investigator's judgment;
pregnancy or lactation in women;
participation in a clinical study in the past 3 months;
history of allergy to ≥2 drugs or foods or known allergy to the drug's constituents.